# US 2020/0002772 A1 · Kit for identifying malignancy, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002772 A1
- Document ID: US20200002772A1
- Status: Published application
- Kind: A1
- Application number: 16/471,320
- Filed: 2017-12-21
- Published: 2020-01-02
- Earliest claimed: 2016-12-21
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology and Research
- Inventors: Bong Hwa GAN; Masafumi INOUE; Veronica DIERMAYR
- Web page: https://patentgrep.com/patent/US20200002772A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a multiplexed amplification reaction kit for identifying a subject suffering from a malignancy sensitive to treatment with an inhibitor of the Wnt signaling pathway, comprising a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion. Also disclosed is a method of identifying sensitivity to an inhibitor of Wnt signaling in a subject suffering from a malignancy, comprising detecting the PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion with a primer pair.

## Claims

### Claim at position 1

1-30. (canceled)

### Claim 31

A method of treating a malignancy in a subject, comprising:
amplifying nucleic acids extracted from a sample from the subject with a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) gene-fusion, and
treating the malignancy in the subject when the PTPRK(e13)-RSPO3(e2) gene fusion is detected.

### Claim 32 (depends on 31)

The method of claim 31, further comprising amplifying the nucleic acids with one or more of primer pairs capable of amplifying a PTPRK(e1)-RSPO3(e2) fusion, primer pairs capable of amplifying a PTPRK(e7)-RSPO3(e2) fusion, and primer pairs capable of amplifying a EIF3E(e1)-RSPO2(e2) fusion, and
treating the malignancy in the subject when one or more of a PTPRK(e1)-RSPO3(e2) fusion, a PTPRK(e7)-RSPO3(e2) fusion, and a EIF3E(e1)-RSPO2(e2) fusion is detected.

### Claim 33 (depends on 31)

The method of claim 31, wherein the sample is formalin-fixed and paraffin embedded (FFPE)-fixed tumor tissue or tissue from fresh-frozen tumor.

### Claim 34 (depends on 31)

The method of claim 31, wherein the nucleic acid is RNA.

### Claim 35 (depends on 31)

The method of claim 31, wherein the amplification step comprises a real time-PCR amplification reaction.

### Claim 36 (depends on 31)

The method of claim 31, wherein the malignancy is a gastrointestinal cancer of the pancreas, stomach, small intestine, large intestine, colon, rectum, or anus.

### Claim 37 (depends on 31)

The method of claim 31, wherein the method comprises treating the subject with an inhibitor of the Wnt signaling pathway.

### Claim 38 (depends on 37)

The method of claim 37, wherein the inhibitor of the Wnt signaling pathway is a porcupine inhibitor selected from:
2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl) acetamide,
2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(6-phenyl pyridazin-3-yl)acetamide,
a compound of the formula (IV):
4-(2-methyl-6,7-dihydropyrazolol [1,5-a]pyrimidin-4(5H)-yl)-4-oxo-N-(6-(pyridin-3-yl)pyradizin-3-yl)butanamide, and
a compound of the formula (V):

### Claim 39

A method of identifying sensitivity to an inhibitor of Wnt signaling in a subject suffering from a malignancy and treating the subject, comprising:
amplifying nucleic acid extracted from a sample from the subject with a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion,
identifying sensitivity to an inhibitor of Wnt signaling when a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion is amplified, and
treating the subject identified to be sensitive to an inhibitor of Wnt signaling.

### Claim 40 (depends on 39)

The method of claim 39, further comprising amplifying the nucleic acid with one or more of primer pairs capable of amplifying a PTPRK(e1)-RSPO3(e2) fusion, primer pairs capable of amplifying a PTPRK(e7)-RSPO3(e2) fusion, and primer pairs capable of amplifying a EIF3E(e1)-RSPO2(e2) fusion, and
identifying sensitivity to an inhibitor of Wnt signaling when one or more of a PTPRK(e1)-RSPO3(e2) fusion, a PTPRK(e7)-RSPO3(e2) fusion, a PTPRK(e13)-RSPO3(e2) fusion, and a EIF3E(e1)-RSPO2(e2) fusion is amplified.

### Claim 41

A composition comprising:
a biological sample comprising RNA obtained from a tumor tissue, and
a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the tumor is from a subject with a gastrointestinal cancer of the pancreas, stomach, small intestine, large intestine, colon, rectum, or anus.

### Claim 43 (depends on 41)

The composition of claim 41, further comprising primer pairs capable of amplifying one or more R-Spondin gene-fusions, wherein the R-Spondin gene-fusions are one or more of a PTPRK(e1)-RSPO3(e2) fusion, a PTPRK(e7)-RSPO3(e2) fusion, and a EIF3E(e1)-RSPO2(e2) fusion.

### Claim 44 (depends on 41)

The composition of claim 41, further comprising one or more of:
control primer pairs capable of amplifying one or more of wild type PTPRK, wild-type EIF3E, wild-type RSPO2, and wild-type RSPO3 sequences;
synthetic oligonucleotide internal control template sequences, and
internal control primer pairs capable of amplifying one or more synthetic internal control template sequences.

### Claim 45 (depends on 41)

The composition of claim 41, further comprising one or more probe sequences complementary to one or more of a sequence in the one or more R-Spondin gene-fusions, a sequence in the one or more wild type genes, and a sequence in the one or more internal control sequences, wherein the one or more probe sequences comprise a fluorophore moiety.
